Abstract
Background:Elderly patients tend to be underrepresented in renal cell carcinoma (RCC) clinical trials. The Sorafenib RCC Integrated Database includes data from six clinical trials and two expanded-access studies evaluating sorafenib monotherapy in >4600 patients with RCC. Using this database, sorafenib tolerability and treatment patterns were analysed according to age group (
Original language | English |
---|---|
Pages (from-to) | 311-318 |
Number of pages | 8 |
Journal | British Journal of Cancer |
Volume | 108 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2013 |
Keywords
- Elderly
- Renal cell carcinoma
- Sorafenib
- Targeted therapies
- Tyrosine kinase inhibitors
ASJC Scopus subject areas
- Cancer Research
- Oncology